Harmony Biosciences (HRMY) Competitors $31.86 -0.17 (-0.54%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HRMY vs. ELAN, LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, and PCVXShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Its Competitors Elanco Animal Health Legend Biotech TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte Harmony Biosciences (NASDAQ:HRMY) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability. Do analysts prefer HRMY or ELAN? Harmony Biosciences currently has a consensus price target of $53.63, suggesting a potential upside of 68.90%. Elanco Animal Health has a consensus price target of $15.17, suggesting a potential upside of 3.70%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Harmony Biosciences is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals hold more shares of HRMY or ELAN? 86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 23.6% of Harmony Biosciences shares are owned by company insiders. Comparatively, 0.9% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, HRMY or ELAN? Harmony Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Which has preferable earnings and valuation, HRMY or ELAN? Elanco Animal Health has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarmony Biosciences$714.73M2.55$145.49M$2.6212.12Elanco Animal Health$4.44B1.64$338M$0.7419.76 Does the media refer more to HRMY or ELAN? In the previous week, Elanco Animal Health had 15 more articles in the media than Harmony Biosciences. MarketBeat recorded 16 mentions for Elanco Animal Health and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.90 beat Elanco Animal Health's score of 0.50 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Overall Sentiment Harmony Biosciences Very Positive Elanco Animal Health Neutral Is HRMY or ELAN more profitable? Harmony Biosciences has a net margin of 20.53% compared to Elanco Animal Health's net margin of 8.43%. Harmony Biosciences' return on equity of 24.32% beat Elanco Animal Health's return on equity.Company Net Margins Return on Equity Return on Assets Harmony Biosciences20.53% 24.32% 15.92% Elanco Animal Health 8.43%7.54%3.57% SummaryHarmony Biosciences beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks. Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.83B$2.90B$5.51B$8.92BDividend YieldN/A2.69%5.38%4.12%P/E Ratio12.1621.4026.2119.84Price / Sales2.55279.63415.30113.63Price / Cash10.7341.8936.4957.06Price / Book2.757.358.005.32Net Income$145.49M-$55.05M$3.15B$248.42M7 Day Performance0.57%2.02%1.72%2.50%1 Month Performance-10.71%6.76%4.63%5.53%1 Year Performance5.83%4.83%35.87%19.65% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.7944 of 5 stars$31.86-0.5%$53.63+68.3%+5.3%$1.82B$714.73M12.12200Positive NewsELANElanco Animal Health2.3312 of 5 stars$13.36-0.7%$15.17+13.5%+2.5%$6.64B$4.43B18.059,000LEGNLegend Biotech2.4528 of 5 stars$33.85-0.4%$76.20+125.1%-21.1%$6.22B$627.24M-57.372,609Positive NewsTGTXTG Therapeutics3.7452 of 5 stars$36.56+1.5%$40.80+11.6%+95.0%$5.80B$329M152.33290GRFSGrifols4.1169 of 5 stars$8.37-4.6%$10.30+23.1%+43.3%$5.75B$7.81B7.1523,822Analyst DowngradeLNTHLantheus4.3333 of 5 stars$80.81+2.0%$130.50+61.5%-0.7%$5.59B$1.53B22.96700TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.54B$516.72M0.00N/AGap DownHigh Trading VolumeNUVLNuvalent3.7087 of 5 stars$75.98+1.3%$115.50+52.0%+3.3%$5.46BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.7553 of 5 stars$101.65+1.0%$172.33+69.5%+27.1%$5.01B$385.69M-17.62380Positive NewsAnalyst RevisionAKROAkero Therapeutics3.6042 of 5 stars$54.03-0.3%$82.50+52.7%+122.0%$4.31BN/A-27.7130PCVXVaxcyte1.8768 of 5 stars$33.25+1.2%$136.50+310.5%-57.2%$4.29BN/A-8.33160News CoveragePositive News Related Companies and Tools Related Companies Elanco Animal Health Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRMY) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRMY Stock Alerts